Accessibility navigation


Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice

Fichtner, I., Pampillon, C., Sweeney, N.J., Strohfeldt, K. and Tacke, M. (2006) Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice. Anti-Cancer Drugs, 17 (3). pp. 333-336. ISSN 0959-4973

Full text not archived in this repository.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Official URL: http://journals.lww.com/anti-cancerdrugs/pages/def...

Abstract/Summary

The benzyl-substituted unbridged titanocene bis-[(p-methoxybenzyl)cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) was tested in vitro against human renal cancer cells (Caki-1), in which it showed an IC50 value of 36 x 10(-6) mol/l. Titanocene Y was then given in vivo in doses of 10, 20, 30, 40 and 50 mg/kg on 5 consecutive days to Caki-1-bearing mice, and it showed concentration-dependent and statistically significant tumor growth reduction with respect to a solvent-treated control cohort. The maximum tolerable dose of Titanocene Y was determined to be 40 mg/kg and it showed significantly better tumor volume growth reduction than cisplatin given at a dose of 2 mg/kg. This superior activity of Titanocene Y with respect to cisplatin will hopefully lead to clinical tests against metastatic renal cell cancer in the near future.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy
ID Code:13746
Uncontrolled Keywords:anti-cancer drug, Caki-1, cisplatin, renal cell cancer, titanocene , SUBSTITUTED ANSA-TITANOCENE, TITANIUM DICHLORIDE, ANTICANCER DRUGS, ORGANIC-CHEMISTRY, IN-VITRO, FULVENES, DERIVATIVES, COMPLEXES, METALLOCENES, CARCINOMA

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation